Caproni 2009

Methods	RCT, active‐controlled Date of study: not stated Location: not stated
Participants	Randomised: 60 participants (age range 28‐67 years (etanercept), 32‐65 years (acitretin), 24 male) Inclusion criteria Participants with moderate‐severe psoriasis (PASI ≥ 10, BSA ≥ 10) Exclusion criteria Pregnancy Had an active infection Past history of malignant tumours Dropouts and withdrawals Not stated
Interventions	Intervention A. Etanercept (n = 30), SC, 50 mg, twice a week, 12 weeks Control intervention B. Acitretin (n = 30), orally, 0.4 mg/kg/day, 12 weeks
Outcomes	Assessment at 12 weeks Primary and secondary outcomes of the trial Not stated Outcomes of the trial Mean PASI at baseline and at 12 weeks PASI 75, PASI 50
Notes	Funding: not stated Declarations of interest: not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote (p 211): "Patients were randomly assigned to one of the two groups" Comment: no description of the method used to guarantee random sequence generation
Allocation concealment (selection bias)	Unclear risk	Comment: no description of the method used to guarantee allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	High risk	Comment: probably open‐label trial, term "blind" not used
Blinding of outcome assessment (detection bias) All outcomes	High risk	Comment: probably open‐label trial, term "blind" not used
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: no description of the method used to manage the missing data. No ITT analyses mentioned
Selective reporting (reporting bias)	Unclear risk	Comment: no primary or secondary outcomes stated